 |
217 Diseases |  |
230 Trials |
|
230 Trials |  |
3979 News |  |
| «12...39404142434445464748495051» |
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P3 trial: SVOSA: Comparison of SEEOX and SOX Regimens in Stage ?B/?C Gastric Cancer Patients (clinicaltrials.gov) - Jan 15, 2015
P3, N=320, Not yet recruiting, Sponsor: Jinling Hospital, China
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: NeoTOP: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status (clinicaltrials.gov) - Jan 15, 2015
P2, N=90, Not yet recruiting, Sponsor: UNICANCER
- ||||||| docetaxel / Generic mfg., epirubicin / Generic mfg.
Trial completion, Trial primary completion date: Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients (clinicaltrials.gov) - Jan 15, 2015
P3, N=724, Completed, Sponsor: Hellenic Oncology Research Group
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Aug 2013
- || 5-fluorouracil / Generic mfg., docetaxel / Generic mfg.
New P3 trial: PEGASE07: Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer (clinicaltrials.gov) - Dec 24, 2014
P3, N=174, Completed, Sponsor: UNICANCER
- |||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=400, Recruiting, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Aug 2013 Not yet recruiting --> Recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Trial primary completion date: GIM9: FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC (clinicaltrials.gov) - Dec 19, 2014
P2, N=47, Completed, Sponsor: Consorzio Oncotech
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | Trial primary completion date: May 2009 --> Jul 2011
- Avastin (bevacizumab) / Roche
Trial primary completion date: Beverly1: Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients (clinicaltrials.gov) - Dec 17, 2014
P2, N=100, Active, not recruiting, Sponsor: UNICANCER
Not yet recruiting --> Completed | Trial primary completion date: May 2009 --> Jul 2011 Trial primary completion date: Apr 2014 --> Apr 2015
- docetaxel / Generic mfg.
Trial termination, Surgery, Metastases: Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer (clinicaltrials.gov) - Dec 17, 2014
P3, N=0, Terminated, Sponsor: UNICANCER
Trial primary completion date: Apr 2014 --> Apr 2015 Active, not recruiting --> Terminated
- ||| everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed: NCI-2012-01514: Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer (clinicaltrials.gov) - Dec 17, 2014
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated Completed --> Active, not recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 17, 2014
P3, N=180, Completed, Sponsor: UNICANCER
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
New P2 trial, Surgery: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (clinicaltrials.gov) - Dec 11, 2014
P2, N=60, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- |||| Enrollment open: MEMORI: Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (clinicaltrials.gov) - Dec 10, 2014
P2, N=75, Recruiting, Sponsor: Technische Universit
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche
New P2 trial, Metastases: Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors (clinicaltrials.gov) - Dec 7, 2014
P2, N=46, Completed, Sponsor: Centro di Riferimento Oncologico - Aviano
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Trial suspension, Trial primary completion date: Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=45, Suspended, Sponsor: University Hospitals, Leicester
Not yet recruiting --> Recruiting Recruiting --> Suspended | Trial primary completion date: May 2014 --> Dec 2015
- Vectibix (panitumumab) / Amgen
Trial primary completion date: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Nov 28, 2014
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended | Trial primary completion date: May 2014 --> Dec 2015 Trial primary completion date: Nov 2015 --> Nov 2016
- cisplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Enrollment closed, Enrollment change: Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer (clinicaltrials.gov) - Nov 28, 2014
P2, N=30, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial primary completion date: Nov 2015 --> Nov 2016 Recruiting --> Active, not recruiting | N=61 --> 30
- carboplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Enrollment open: Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer (clinicaltrials.gov) - Nov 25, 2014
P2, N=200, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Recruiting --> Active, not recruiting | N=61 --> 30 Not yet recruiting --> Recruiting
- | New P2 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 24, 2014
P2, N=460, Recruiting, Sponsor: UNICANCER
- || melphalan / Generic mfg.
New P3 trial: DSMM-II: Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (clinicaltrials.gov) - Nov 12, 2014
P3, N=549, Completed, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
- ||||| New P2 trial: MEMORI: Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (clinicaltrials.gov) - Nov 10, 2014
P2, N=75, Not yet recruiting, Sponsor: Technische Universit
- lapatinib / Generic mfg., paclitaxel / Generic mfg.
Trial termination: Phase II Neoadjuvant in Inflammatory Breast Cancer (clinicaltrials.gov) - Nov 5, 2014
P2, N=15, Terminated, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Completed --> Terminated; Slow accrual.
- | Enrollment change, Metastases: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Oct 30, 2014
P2/3, N=714, Recruiting, Sponsor: Krankenhaus Nordwest
Completed --> Terminated; Slow accrual. N=590 --> 714
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=245, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=590 --> 714 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2008 --> Dec 2012
- docetaxel / Generic mfg.
Trial completion: Breast Cancer Treated by Neoadjuvant Chemotherapy (clinicaltrials.gov) - Oct 2, 2014
P2, N=264, Completed, Sponsor: Centre Jean Perrin
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2008 --> Dec 2012 Recruiting --> Completed
- | GSK2302024A / GSK
Enrollment change, Trial termination, Trial primary completion date: INDUCT: Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (clinicaltrials.gov) - Sep 28, 2014
P2, N=60, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=250 --> 60 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Aug 2014; Study termination due to negative Ph III of another study product from same technology platform.
- ||| Vyloy (zolbetuximab) / Astellas
Enrollment closed, Combination therapy, Metastases: FAST: Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (clinicaltrials.gov) - Sep 28, 2014
P2, N=210, Active, not recruiting, Sponsor: Ganymed Pharmaceuticals AG
N=250 --> 60 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Aug 2014; Study termination due to negative Ph III of another study product from same technology platform. Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Sep 15, 2014
P2, N=162, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Combination therapy, Metastases: A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors (clinicaltrials.gov) - Sep 15, 2014
P1, N=111, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial: A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer. (clinicaltrials.gov) - Aug 26, 2014
P2, N=11, Completed, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Enrollment open: The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients (clinicaltrials.gov) - Aug 19, 2014
P2, N=60, Recruiting, Sponsor: Lagos State University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | epirubicin / Generic mfg.
New P4 trial: NMIBCIVT: Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 12, 2014
P4, N=240, Recruiting, Sponsor: Mansoura University
- metformin / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: PACT-17: Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 11, 2014
P2, N=82, Active, not recruiting, Sponsor: IRCCS San Raffaele
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2013 --> Dec 2014
- ||||| cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Enrollment closed: planB: Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (clinicaltrials.gov) - Aug 8, 2014
P3, N=2448, Active, not recruiting, Sponsor: West German Study Group
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2013 --> Dec 2014 Recruiting --> Active, not recruiting
- || Trial primary completion date: MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (clinicaltrials.gov) - Aug 4, 2014
P4, N=226, Recruiting, Sponsor: Agendia
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Dec 2015
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
New P4 trial, Combination therapy, Metastases: Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer (clinicaltrials.gov) - Aug 4, 2014
P4, N=120, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrollment change, Trial termination, Trial primary completion date, Surgery, Metastases: Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 1, 2014
P2, N=29, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Dec 2013 --> Dec 2015 N=192 --> 29 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Aug 2013; company withdrew interest
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Trial completion: Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 30, 2014
P0, N=25, Completed, Sponsor: Dana-Farber Cancer Institute
N=192 --> 29 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Aug 2013; company withdrew interest Active, not recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer (clinicaltrials.gov) - Jul 27, 2014
P2, N=105, Completed, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P3, N=4808, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen, Takeda
Trial termination, Combination therapy: EOXP: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=17, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Terminated; Closed due to slow accrual
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
Trial termination: BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (clinicaltrials.gov) - Jul 8, 2014
P3, N=3509, Terminated, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting --> Terminated; Closed due to slow accrual Active, not recruiting --> Terminated
- Vectibix (panitumumab) / Amgen, Takeda
Enrollment change, Trial termination, Combination therapy: EOXP: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=17, Terminated, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Terminated N=30 --> 17 | Recruiting --> Terminated; Closed due to slow accrual
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jul 1, 2014
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 17 | Recruiting --> Terminated; Closed due to slow accrual Initiation date: Sep 2014 --> Jun 2014
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jul 1, 2014
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Sep 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jun 2014
- | Enrollment change: CBCSG010: Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer (clinicaltrials.gov) - Jun 27, 2014
P3, N=636, Recruiting, Sponsor: China Breast Cancer Clinical Study Group
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jun 2014 N=520 --> 636
- | New P2 trial, Metastases: SEED: Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma (clinicaltrials.gov) - Jun 27, 2014
P2, N=98, Recruiting, Sponsor: Rigshospitalet, Denmark
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Jun 27, 2014
P3, N=4800, Recruiting, Sponsor: Hoffmann-La Roche
N=520 --> 636 Active, not recruiting --> Recruiting
- |||| rilotumumab (AMG 102) / Amgen
Trial primary completion date, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Jun 5, 2014
P3, N=600, Recruiting, Sponsor: Amgen
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Mar 2016
- ||||| rilotumumab (AMG 102) / Amgen
Enrollment change, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Jun 5, 2014
P3, N=600, Recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Mar 2016 N=450 --> 600
- cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Enrollment change: The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients (clinicaltrials.gov) - May 29, 2014
P2, N=60, Not yet recruiting, Sponsor: Lagos State University
N=450 --> 600 N=184 --> 60